Zobrazeno 1 - 10
of 242
pro vyhledávání: '"Steven D. Pearson"'
Autor:
Matthew R. Stutz, Nicholas P. Dylla, Steven D. Pearson, Paola Lecompte-Osorio, Ravi Nayak, Maryam Khalid, Emerald Adler, Jaye Boissiere, Huaiying Lin, William Leiter, Jessica Little, Amber Rose, David Moran, Michael W. Mullowney, Krysta S. Wolfe, Christopher Lehmann, Matthew Odenwald, Mark De La Cruz, Mihai Giurcanu, Anne S. Pohlman, Jesse B. Hall, Jean-Luc Chaubard, Anitha Sundararajan, Ashley Sidebottom, John P. Kress, Eric G. Pamer, Bhakti K. Patel
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Here, via applying metagenomics and metabolomics analyses, the authors show that fecal microbiota composition and microbiota-derived metabolites predict the trajectory of respiratory function and death in patients with severe SARS-Cov-2 infection, su
Externí odkaz:
https://doaj.org/article/a1344fdb84c44035942e569d90a92547
Autor:
Paola Lecompte-Osorio, Steven D. Pearson, Cole H. Pieroni, Matthew R. Stutz, Anne S. Pohlman, Julie Lin, Jesse B. Hall, Yu M. Htwe, Patrick G. Belvitch, Steven M. Dudek, Krysta Wolfe, Bhakti K. Patel, John P. Kress
Publikováno v:
Critical Care, Vol 25, Iss 1, Pp 1-7 (2021)
Abstract Purpose In acute respiratory distress syndrome (ARDS), dead space fraction has been independently associated with mortality. We hypothesized that early measurement of the difference between arterial and end-tidal CO2 (arterial-ET difference)
Externí odkaz:
https://doaj.org/article/f19f7338008a497a81a43158e379f615
Autor:
Steven D Pearson, Prabhjot Singh, Francesca Beaudoin, Jon Campbell, Lindsey Schapiro, Sarah K Emond, Caroline Pearson
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 12 (2023)
Digital health technologies (DHTs) are a broad and rapidly innovating class of interventions with distinctive pathways for development, regulatory approval, uptake and reimbursement. Given the unique nature of DHTs, existing value assessment framew
Externí odkaz:
https://doaj.org/article/4cc8fc592c4d48c7b0a6e8facae7f7d1
Autor:
Mrinmayee, Joshi, Steven J, Atlas, Molly, Beinfeld, Richard H, Chapman, David M, Rind, Steven D, Pearson, Daniel R, Touchette
Publikováno v:
Value in Health. 26:823-832
Nadofaragene firadenovec is a gene therapy for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) undergoing FDA review. Pembrolizumab is approved for treating BCG-unresponsive NMIBC patients with carcinoma in-situ (CIS). We evaluated the co
Autor:
Jeffrey A Tice, Surrey M Walton, Jyotirmoy Sarker, Ashton Moradi, Janet N Chu, Belen Herce-Hagiwara, Shahariar Mohammed Fahim, Foluso Agboola, David Rind, Steven D Pearson
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 29:576-581
Publikováno v:
Value in Health. 26:378-383
To evaluate the influence of drug price dynamics in cost-effectiveness analyses (CEAs).We evaluated scenarios involving typical US drug price increases during the exclusivity period and price decreases after the loss of exclusivity (LOE). Worked exam
Autor:
Steven D. Pearson, Julie Lin, Matthew R. Stutz, Paola Lecompte-Osorio, Anne S. Pohlman, Krysta S. Wolfe, Jesse B. Hall, John P. Kress, Bhakti K. Patel
Publikováno v:
Annals of the American Thoracic Society. 19(9)
Autor:
Victoria Lancaster, Marina Richardson, Francesca L Beaudoin, Patricia G Synnott, David M Rind, Belén Herce-Hagiwara, Jon D Campbell, Steven D Pearson
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 28:1316-1320
Publikováno v:
Journal of Comparative Effectiveness Research. 11:999-1010
Scientific advancements, new US FDA approval pathways and limited competition have contributed to rapid growth in the number of approved rare disease treatments in recent years. While the rising numbers of orphan drug approvals are a sign of success,
Autor:
Molly Beinfeld, Kai Yeung, Melanie D Whittington, Rasheed Mohammed, Emily Nhan, Steven D Pearson
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 28:903-909